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Abstract 
Background: Costs attributable to criminal activity are a major component of the economic 
burden of substance use disorders, yet there is a paucity of empirical evidence on this topic. 
Our aim was to estimate the costs of crime associated with different forms and intensities of 
stimulant use. 
Methods: Retrospective cohort study, including individuals from three prospective cohorts in 
Vancouver, Canada, measured biannually (2011-2015), reporting stimulant use at baseline 
assessment. Monthly crime costs included policing, court, corrections, and criminal victimization 
(2016 CAD). We estimated monthly crime costs associated with mutually exclusive categories 
of crack, cocaine, methamphetamine, and polystimulant use, stratified by daily/non-daily use, 
relative to stimulant abstinence, as well as the independent effects of treatment (opioid agonist 
(OAT) and other addiction treatment). We used a two-part model, capturing the probability of 
criminal activity and costs of crime with generalized linear logistic and gamma regression 
models, respectively, controlling for age, gender, education, homelessness, mental health 
issues, employment, prior incarceration, alcohol and opioid use. 
Results: The study sample included 1,599 individuals (median age 39, 65.9% male) assessed 
over 5299 biannual interviews. Estimates of associated monthly crime costs ranged from $5449 
[95%C.I.: $2180, $8719] for non-daily polystimulant use, to $8893 [$4196, $13,589] for daily 
polystimulant use. Cost differences between daily/non-daily use, injection/non-injection, and 
stimulant type were not statistically significant. Drug treatment was not associated with lower 
monthly crime costs in our sample. 
Conclusions: Substantial crime-related costs were associated with stimulant use, emphasizing 
the urgency for development and implementation of efficacious treatment regimens. 
  
1.0 Introduction  
Criminal activity is one of the largest components of the total societal costs attributable to illicit 
drug use in Canada and around the world. It is estimated that the direct costs (e.g. healthcare, 
law enforcement) of illicit drug use were as high as $3.57 billion (CAD) in Canada in 2002, with 
law enforcement costs comprising over 65% (Rehm et al., 2007). Direct costs have been 
estimated at $52.2 billion (USD) in the United States in 2007, with crime costs accounting for 
over 69% (National Drug Intelligence Center, 2011). Worldwide, stimulant use disorders are the 
second most common illicit drug use disorder after opioids, and the majority of the disease 
burden associated with stimulant use comes from cocaine (crack cocaine and cocaine 
hydrochloride) and amphetamines (specifically methamphetamine (MA)) (Degenhardt et al., 
2014). Globally, MA use is more problematic than cocaine, due to dramatic physiological 
changes and sensitization in chronic users, as well as significantly higher prevalence beyond 
North and South America (Degenhardt et al., 2014; Degenhardt et al., 2013). In a literature 
review of studies estimating the economic benefits of addiction interventions, McCollister and 
French (2003) found that reductions in crime accounted for more than half of the total economic 
benefit in the majority of studies. More recent studies for treatment interventions found criminal 
activity to account for over 75% of accumulated lifetime direct costs for individuals with opioid 
use disorders (Nosyk et al., 2012), as well as a major component of total costs in other studies 
(Byford et al., 2013; Dijkgraaf et al., 2005; Zarkin et al., 2005).  
High rates of drug use, particularly stimulants, among criminals have been observed in 
populations of arrestees and prison inmates (Karberg and James, 2005; ONDCP, 2014), 
however, the mechanism for the association between stimulant use and criminal activity is 
multifaceted (Goldstein, 1985). Pharmacological effects of stimulant use are well-known, and 
there is evidence that the risk of psychotic episodes and aggressive behavior increases in long-
term users of methamphetamine (Harro, 2015), as well as similar neurocognitive problems in 
chronic cocaine users (Bolla et al., 1998). Furthermore, acute effects of drug use in reducing 
impulse control have been found to be more pronounced in stimulants than opiates (Badiani et 
al., 2011). Economic motivations for criminal activity stemming from stimulant use (such as 
acquisitive crime and other income generating activities) are perhaps the most direct 
mechanism for this relationship, given the high cost of illicit drugs (Bennett et al., 2008; Hepburn 
et al., 2016; Wilkins and Sweetsur, 2011).  
Despite a large literature on the association between drug use and criminal behaviour, there 
are few studies examining the effects of stimulant use on criminal activity and associated costs. 
Flynn et al. (1999) estimated a range of $18,244 - $33,609 for yearly costs of crime of among 
untreated cocaine-dependent individuals, with significantly lower costs during and after 
treatment. Oser et al. (2011) found that stimulant use was associated with increased criminal 
activity amongst rural drug users, compared to no stimulant use. Vaughn et al. (2010) found that 
crack cocaine use was associated with higher odds of violence than powdered cocaine. 
However, the authors concluded that other heterogeneity in users was largely contributing to 
these differences. In a systematic review and meta-analysis, Bennett et al. (2008) found that the 
odds of offending was 1.9 times higher for amphetamine users and 6 times higher for crack 
users, compared to non-drug users.  
To date, no effective pharmacological treatments have been identified for stimulant use 
disorders (Fischer et al., 2015). Contingency management and cognitive behavioural therapies 
(CM/CBT) have shown efficacy in trial-based settings, particularly short-run CM interventions, in 
which participants receive a prize or reward for maintaining abstinence (DeFulio et al., 2009; 
Jaffe et al., 2007; McKay et al., 2010; Rawson et al., 2006; Schumacher et al., 2007; Shoptaw 
et al., 2005). However, treatment modalities are far from standardized, and treatment utilization 
and outcomes are not systematically tracked in the province of British Columbia or elsewhere 
across Canada.  
The goal of this study was to test a series of hypotheses about the association between 
stimulant use and crime costs. First, that stimulant use (stratified by type and use intensity) is 
positively associated with crime costs, relative to stimulant abstinence; second, that higher 
frequency of use is associated with higher crime costs within stimulant types; third, that different 
stimulant types and polystimulant use are associated with different levels of crime costs, holding 
intensity of use constant; and finally, that injection use is associated with higher crime costs 
than non-injection use within stimulant types.  
2.0 Methods 
2.1 Study Sample 
Data for this analysis was derived from a series of ongoing open prospective cohort studies, 
conducted in Vancouver, involving people who use drugs, including the At-Risk Youth Study 
(ARYS), the AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), and the 
Vancouver Injection Drug Users Study (VIDUS). The VIDUS study follows HIV-negative adults 
who inject drugs while the ACCESS study follows HIV-positive adults who inject drugs 
(Strathdee et al., 1997; Wood et al., 2009). ARYS is made up of street-involved youth aged 14-
26 who report use of drugs other than, or in addition to, cannabis (Wood et al., 2006a; Wood et 
al., 2006b). Sampling and follow-up methodologies have been described in previous studies and 
surveys were structured identically to allow for combined longitudinal analysis (Strathdee et al., 
1997; Tyndall et al., 2003; Wood et al., 2006a; Wood et al., 2006b). At baseline and 
semiannually thereafter, participants completed an interviewer-administered questionnaire and 
received $30 CAD at each visit. All studies were approved by the University of British 
Columbia/Providence Health Care Research Ethics Board.  
Individuals included in this analysis entered the study between September 2005 and 
December 2013, and the data were collected from December 2011 to May 2015 to coincide with 
the inclusion of survey items comprehensively capturing criminal activity. During this period, 
individuals could have a maximum of seven biannual assessments. All individuals who had 
completed at least one follow-up interview during this period were eligible for inclusion. In 
addition, individuals were excluded if they had never reported stimulant use prior to the start of 
our sample period or at baseline. The reference group for our main analysis was past stimulant 
users who reported abstinence (no use of any stimulant drugs in the previous six months) at the 
time of assessment.  
2.2 Crime Costs  
Detailed survey questions included both the type and frequency of criminal acts committed in 
the past 30 days, categorized as violent offenses (such as assault, murder and weapons 
offenses), property crimes, drug dealing, sex work, legal status violation, disorderly conduct, 
and other offenses. Questions also included number of days incarcerated, on parole or under 
legal supervision in the past 30 days. Costs were assigned to each act by both the type of 
crime, as well as unit costs for the relevant expenditure categories. Monthly crime costs 
included all self-reported incidents of criminal activity, regardless of whether or not an individual 
was arrested for a particular act. Costs were calculated from a societal perspective, and 
included costs regardless of who incurred them or whether they corresponded directly to 
budgetary expenditures (Garrison et al., 2010). Total monthly crime costs were the combined 
costs of incident costs (police response), arrest processing and court costs for the criminal 
justice system, and criminal victimization (Krebs et al., 2014) (unit costs are presented in 
Supplementary material). Incident costs were derived from the overall operating budget of the 
Vancouver Police department, which captured the costs of police response to crime scenes, 
whether or not an arrest was made (Krebs et al., 2014). Arrest processing and court costs were 
assigned to acts where an individual reported being arrested, and incarceration costs to days an 
individual reported being incarcerated or on parole in the previous month. Victimization costs 
included medical expenses, cash losses and pain-and-suffering based on jury-compensation for 
victims (McCollister et al., 2010). Victimization costs were applied to violent offenses based on 
estimates for assaults, and property crimes as a weighted average based on cost estimates for 
break and enter and theft in McCollister et al. (2010), and the observed proportions of each type 
of crime in Vancouver, derived from the Vancouver Police Department and Statistics Canada 
(Krebs et al., 2014; McCollister et al., 2010). Incidents of sex work and drug dealing were only 
assigned costs if individuals reported being arrested, given that police are likely responding to 
only a fraction of total incidents (which we define as an individual reporting arrest), and were 
excluded from victimization costs, given the argument that these activities can be viewed as 
transactions with no direct costs of victimization (Dijkgraaf et al., 2005; Rajkumar and French, 
1997; Zarkin et al., 2012). Monthly crime costs were adjusted to account for the proportion of 
days incarcerated in the past month. 
2.3 Measures 
Our primary independent variables were indicators of stimulant use in the past six 
months, grouped into one of eight mutually exclusive categories (Figure 1), including any use of 
powdered cocaine, daily or non-daily use of crack cocaine or methamphetamine, concurrent use 
of more than one stimulant drug (polystimulant), with daily use for polystimulant users specified 
as daily use of at least one stimulant, and a reference group of stimulant abstinent individuals. 
In addition to these categories, we also estimated the crime costs associated with individuals in 
treatment (either OAT or other non-OAT treatment modalities) in the previous six months.  
Baseline control variables included sex, education (completion of high school), and a 
history of incarceration. These were included to control for demographic and socioeconomic 
characteristics, as well as potential predisposition for criminality (Krebs et al., 2014). Time 
varying control variables included linear and quadratic age trends, homelessness, formal 
employment (full- or part-time), accessing mental health treatment, binge alcohol use, and 
opioid use, all in the previous six months. Indicators for homelessness and addiction treatment 
were included to control for their potential association with criminal activity, both directly and 
mediated through changes in drug use, specifically among opioid co-users (DeBeck et al., 2007; 
Schwartz et al., 2010). A variable for accessing mental health treatment was included to control 
for the potential association between mental health problems, drug use and criminal activity 
(Bolla et al., 1998; Harro, 2015).  To test our hypothesis on the effects of injection drug use, we 
regressed crime costs on indicators for injection and concurrent injection/non-injection use in a 
subgroup of methamphetamine users. In this subgroup analysis, control variables were included 
for polystimulant use, and the reference group was non-injection MA users. 
2.4 Statistical Analysis  
Estimates for the association between stimulant use and monthly crime costs were 
derived using a two-part multiple regression model to account for the large number of 
observations with zero-valued monthly crime costs. The first part modeled the probability of 
having non-zero crime costs using a logit regression, while the second part estimated the level 
of non-zero costs using a Generalized Linear Model (GLM). For the GLM specification, we 
selected a log link function, and used modified Park tests to choose a gamma distribution for 
crime costs. We also estimated cluster-robust (Huber-White) standard errors to account for 
within-individual correlation of error terms resulting from repeated measures. We estimated 
marginal effects for both parts of the model, estimated at each individual’s respective covariate 
values. The resulting average marginal effects (AME) were interpreted as the population effect 
associated with stimulant use on monthly costs of crime, and were not conditional on individuals 
having positive crime costs. Data was prepared in SAS 9.4, and the analysis was conducted in 
Stata 14.1. 
Given that cost data were derived from self-reported accounts of criminal activity, we chose 
a conservative approach consistent with Krebs et al. (2014) and excluded the top two percent of 
total crime cost observations from our final sample. This was done to limit the effect of 
extremely high cost and potentially uncertain responses on the representativeness of our 
results. 
In sensitivity analysis, we examined two alternative scenarios to our baseline model, 
which considered costs from a societal perspective. First, we considered the perspective of a 
third-party payer, which only considered costs incurred by the criminal justice system (arrests, 
incidents and court costs) and not victimization costs. Second, we estimated our model using 
only costs of arrests and court proceedings, and not costs of incidents which were reported in 
survey assessments, but did not result in arrest. Finally, we estimated our model with the top 
outliers included, as well as a more restrictive upper bound in which we removed the top five 
percent of cost outliers for comparison. 
3.0 Results 
3.1 Study Sample Characteristics 
A total of 1599 individuals (contributing 5299 observations, median of 3 [IQR: 2-4] per individual) 
met the primary inclusion criteria and 83.2% of individuals completed at least two assessments 
during the study period. Our sample was over 65.9% male, with 71.4% of individuals reporting 
prior incarceration at baseline. Summary statistics for our sample are presented in Table 1. 
Table 2 presents summary statistics for monthly crime costs by expenditure category, while 
Figure 1 depicts the number of observations by stimulant use category, and Figure 2 presents 
monthly crime costs by stimulant use category.  Approximately half of all observations with 
crack cocaine and MA use (48.6% and 51.5% respectively) were individuals using only one type 
of stimulant drug, compared to 25.5% of powdered cocaine users. Additionally, individuals 
reported no criminal activity and had zero-valued monthly crime costs in 79.6% of all 
observations.  
3.2 Results of Two-Part Regression Models 
In the baseline specification of our two-part model regression analysis, we found a 
positive and significant association between crime costs and MA, polystimulant and cocaine 
use, relative to abstinence (p < 0.05). AME estimates for associated monthly crime costs were 
$5449 [95% C.I. $2180, $8719] for non-daily polystimulant use, $5723 [$2013, $9434] for non-
daily MA use, $5845 [$663, $11,028] for daily MA use, $5864 [$1220, $10,508] for powdered 
cocaine use, and $8893 [$4196, $13,589] for daily polystimulant use (Table 3). In addition to our 
comparison between stimulant use and stimulant abstinence, we also tested differences in 
crime costs between stimulant use categories, holding intensity of use constant (e.g. daily MA 
vs. daily crack cocaine, or non-daily MA vs. non-daily crack cocaine). We could not reject the 
null hypothesis of no difference in associated crime costs across stimulant use categories for 
either daily or non-daily use intensities. Although estimates for crime costs associated with daily 
use were higher within each stimulant use category, these differences were not significant. 
Finally, estimates for independent associations between OAT and non-OAT treatments, and 
monthly crime costs were not significant (Table 3). 
In addition to our baseline model, we also estimated monthly crime costs associated with 
injection vs. non-injection use in a subgroup of MA users. Neither estimate for injection or 
concurrent injection/non-injection MA use was significantly associated with higher crime costs 
relative to non-injection MA use (Table 4). 
3.3 Sensitivity Analysis 
In sensitivity analysis of alternative payer perspectives, results were similar in direction 
and statistical significance, with slightly smaller magnitude when including only third-party payer 
costs. For estimates including arrests and court costs only, the magnitude of estimates was 
lower than either societal or third-party payer perspectives, and only daily methamphetamine, 
daily and non-daily polystimulant use categories were significantly higher than abstinence. 
Results of testing differences between daily and non-daily use as well as across drug types 
were robust. Lastly, when the top two percent of monthly crime cost observations were included 
in the sample, most associations were no longer significantly different from abstinence, with the 
exception of the daily polystimulant use, and results were robust, though smaller in magnitude, 
when the top five percent of monthly crime costs were excluded (results available in 
Supplementary material). 
4.0 Discussion 
4.1 Findings 
We found a positive and significant association between stimulant use and monthly 
crime costs for powdered cocaine, MA and polystimulant use, relative to stimulant abstinence. 
We did not find significant differences between levels of use intensity within stimulant types, 
across stimulant types, or between routes of administration of methamphetamine.  
Estimates for both OAT and other substance use treatment (non-OAT) did not allow us 
to conclude that either had independently beneficial effects amongst users in our analytic 
sample (i.e. a significant negative association with monthly crime costs). Since neither treatment 
was specifically targeted toward stimulant use, we were not necessarily expecting to observe a 
significant association with lower crime costs among those in our analytic sample, however, we 
wanted to consider the potential for positive spillover effects and increased pro-social behaviour 
resulting from any type of addiction treatment. This was informed by results from Krebs et al. 
(2014) and Krebs et al. (2016), which found that OAT was more effective in reducing crime 
costs among opioid users who were co-using stimulants. Although estimates for OAT in our 
study were not independently associated with lower crime costs, opioid users comprised only a 
subset of our analytic sample, as the inclusion criteria was not related to opioid use or OAT 
history. Additionally, our reference group for OAT was individuals not receiving OAT, regardless 
of concurrent stimulant or opioid use and cannot be directly compared to estimates reported 
elsewhere for OAT treatment among opioid users.  
Our finding of positive and significant associations between monthly crime costs and 
drug use for the majority of stimulant use categories was consistent with other studies (Bennett 
et al., 2008; Oser et al., 2011), and similar in magnitude to crime cost estimates of drug users 
in-relapse or out-of-treatment, compared to in-treatment or abstinent (Flynn et al., 1999; Krebs 
et al., 2014; Krebs et al., 2016). Our finding that monthly crime costs associated with powdered 
cocaine use were not significantly different than crack cocaine was consistent with Vaughn et al. 
(2010), who found no differences in violent behavior after controlling for contextual variables 
and co-morbid disorders. Furthermore, our result that powdered cocaine, but not crack cocaine 
use, was significantly associated with higher monthly crime costs relative to stimulant 
abstinence, was contrary to results in Stewart et al. (2014) suggesting that crack cocaine was 
associated with higher amounts criminal activity. Due to differences in measurement for both 
drug use and criminal activity, however, these results are not directly comparable with our 
estimates. Additionally, this result may be due, in part, to a high proportion of injection users of 
powdered cocaine in our study, relative to the general population (Novak and Kral, 2011), which 
has shown to be associated with other high-risk behaviours (Lloyd-Smith et al., 2009; Tyndall et 
al., 2003). 
The result that daily use was not associated with higher crime costs than non-daily use 
was somewhat surprising, however, this may have been affected by less precise estimates 
given the rarity of criminal activity and smaller group sizes, once users were stratified by daily 
and non-daily use. In addition, our measure for stimulant use intensity was may not have been 
sensitive enough to detect these differences. As such, the association between stimulant use 
intensity and crime costs remains an open question for future research. The literature on 
substance use and crime, as well as the neurological effects of binge stimulant use suggests 
that intensity of use may be an important moderator of the effects of drug use. In addition to 
nearly 80% of observations having zero-valued crime costs, over 60% of stimulant using 
individuals in our analytic sample reported no criminal activity throughout the duration of their 
follow-up. This illustrates what is typically the case; that criminal activity is a relatively rare 
event, and crime costs are characterized by a small number of events and individuals having a 
substantial influence on the total costs. 
4.2 Limitations  
There are several potential limitations to our analysis. First, that our data was collected 
via self-report surveys. Survey data has demonstrated to be a reliable measure for arrests when 
recall windows are appropriately short, with no consistent bias toward over or under reporting 
(Johnson et al., 2005). Since our survey instruments only asked respondents to report criminal 
activity from the past 30 days, it is unlikely that the length of recall time was a significant 
problem. In the case of drug use in particular, other studies have found that potential bias may 
go in the direction of underreporting, given the possibility of respondent mistrust of interviewers 
when reporting illegal activity (Johnson and Golub, 2007). Given that our analytic sample was 
from a longitudinal cohort in which over 80% of individuals were measured over multiple cycles, 
trust between respondents and interviewers was likely stronger than in cross-sectional surveys 
where respondents were only interviewed once.  
While we accounted for observable heterogeneity by including a number of a priori-
specified control variables in our regression analysis, there was still potential for unmeasured 
confounding. A common method to address this problem in panel data is fixed effects 
estimation, which uses each individual as his or her own control to eliminate time-invariant 
heterogeneity, whether observed or unobserved. Although this specification is not currently 
available for two-part model estimation packages, we were able to re-estimate Part I of our 
model using a fixed-effects logit specification for the probability of an individual having any crime 
costs in the previous six months. While this reduced the size of our analytical sample, as we 
could only estimate within-individual effects among the subset of those who exhibited variation 
in criminal activity over time, fixed-effects logit estimates for stimulant use were consistent in 
direction with Part I of our baseline model, though most estimates were smaller in magnitude 
and only daily MA use remained significantly higher than stimulant abstinence (Supplementary 
material). 
Finally, caution must be exercised when generalizing these results. Injection drug use 
was a criterion for selection into the VIDUS and ACCESS studies, while 49.7% of individuals 
from the ARYS cohort included in our sample had used injection drugs. Our analytic sample 
was located in a unique urban Canadian setting, characterized by socioeconomic 
marginalization and easy access to illicit drug markets (DeBeck et al., 2007; Richardson et al., 
2015; Ti et al., 2014). As a result, there are a number of contextual effects that may be quite 
different when dealing with a broader cross-section of stimulant users, including structural 
factors such as higher levels of policing activity and higher probabilities of police interaction and 
arrests among this cohort than might be the case in other settings. 
4.3 Implications 
As there are no evidence-based pharmacologic approaches for treating stimulant use 
disorders, and other promising forms of psychosocial therapy have yet to show persistent 
effects across settings or over longer time horizons, the implications of this study in estimating 
the benefits of treatment are largely hypothetical. The treatment variables included in our 
analysis represented an exploratory assessment of the potential for positive effects for stimulant 
users from non-stimulant-specific treatments, however, we would expect an effective, evidence-
based treatment regimen for stimulant use disorders to have considerably larger effects. For 
example, if an effective treatment regimen was identified and capable of generating an 80% 
reduction in crime costs, similar to what has been recently estimated for OAT and opioid users 
(Krebs et al., 2014; Krebs et al., 2016), as well as individuals in long-term residential treatment 
for cocaine use disorders (Flynn et al., 1999), there are potential average monthly cost savings 
of $4691 per cocaine user, $4676 per daily MA user, and $7114 per daily polystimulant user 
treated. This is in addition to many other potential health benefits and cost savings, such as 
reduced health care costs, that could be generated by an effective treatment program (Baser et 
al., 2011; French and Martin, 1996). Even with all tangible costs such as policing, healthcare 
and victimization included, these estimates can still be considered a lower bound for the overall 
societal costs of criminal activity (Basu et al., 2008). 
4.4 Conclusion 
Most types of stimulant use were associated with increased monthly crime costs. If new, 
effective treatment modalities for stimulant use disorders can generate similar reductions in 
crime costs to what has been estimated for OAT, there are potentially large economic benefits, 
in addition to public health benefits, to reap from such treatments.  
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